Blog

https://www.genetionary.org

The PREDI-LYNCH project is dedicated to advancing early detection and personalised prevention of Lynch syndrome, a hereditary condition that predisposes individuals to colorectal, endometrial, and several other types of cancer.

Through collaboration with leading medical institutions and researchers, the project aims to refine risk assessment tools that combine genetic markers, family history, and lifestyle factors. This holistic approach enables healthcare providers to offer tailored screening and prevention strategies, ultimately reducing cancer incidence and improving long-term patient outcomes.

AI models are exceptionally good at finding subtle, hidden correlations within vast datasets—clues that might be impossible for the human eye to spot. Within the PREDI-LYNCH project, we feed our algorithms integrated clinical, lifestyle, and molecular data from thousands of historical cohorts.

Over time, the AI learns to identify exactly which combinations of factors indicate a higher risk of early-onset colorectal or endometrial cancers.

The result? A highly personalised risk score that empowers doctors to adapt surveillance schedules before a tumour even has the chance to develop.

PREDI-LYNCH also emphasises patient education and accessibility, ensuring that risk prediction tools are user-friendly and available to diverse populations. By bridging the gap between research and clinical practice, the project strives to empower individuals and clinicians alike with actionable insights for precision medicine in hereditary cancer prevention.

PREDI-LYNCH Advancing early detection and personalized prevention of Lynch syndrome

One of the key messages from the paper is that community-based systemic anti-cancer therapy is not simply about moving treatment closer to home. Successful implementation depends on getting the fundamentals right:

• Clear clinical governance and accountability between hospital and community services.
• Investment in skilled multidisciplinary teams and advanced nursing leadership.
• Shared digital infrastructure that supports safe communication and continuity of care.
• Strong collaboration across organisations and professions.
• Ongoing evaluation to ensure services remain safe, equitable and responsive to patients’ needs.

https://www.sciencedirect.com/science/article/pii/S0749208126001671?dgcid=author

People with Lynch syndrome have a much higher risk of developing colorectal cancer, so they have regular colonoscopies to find and remove precancerous growths (adenomas). Artificial intelligence (AI) can help doctors spot these growths during colonoscopy in people at average risk, but it was unclear whether it would also help in people with Lynch syndrome.

This international study compared standard high-definition colonoscopy with colonoscopy assisted by an AI system called CAD EYE in 733 people with Lynch syndrome across nine specialist centres in Europe.

The researchers found that AI did not significantly increase the number of patients in whom adenomas were detected.

The study also assessed whether the AI could correctly identify whether detected polyps were likely to be precancerous (neoplastic) or non-precancerous (non-neoplastic). While the AI showed good accuracy, it did not perform better than experienced specialist endoscopists, limiting its added value in expert Lynch syndrome surveillance programmes.

Overall, the study suggests that adding AI to colonoscopy does not meaningfully improve adenoma detection or polyp characterisation in specialist surveillance for people with Lynch syndrome, where colonoscopies are already performed by highly experienced endoscopists using high-quality equipment.

https://www.thelancet.com/journals/langas/article/PIIS2468-1253%2826%2900163-9/fulltext

Question… What barriers do we still overlook for people living with cancer?

https://lnkd.in/p/dkFcYFHh

Conclusion

This study characterised neoplasia(unregulated process of cell proliferation that results in a tumour) detection in Lynch syndrome and confirmed higher detection rates with high-quality procedures, supporting the need to benchmark quality standards and neoplasia detection outcomes.

https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2888-6567

https://www.thelancet.com/action/showPdf?pii=S2468-1253%2826%2900114-7

Bottom line

This is one of the largest and most important aspirin prevention studies ever conducted in people with Lynch syndrome.

It suggests:

• ✅ Daily aspirin can help reduce the risk of Lynch syndrome–related cancers.
• ✅ 100 mg daily appears to provide similar protection to 600 mg for many people.
• ✅ 100 mg causes fewer side effects and much less serious bleeding.
• ⏳ The researchers will continue following participants for another five years, and those longer-term results should provide even stronger evidence about the best aspirin dose.